Tempest Therapeutics, Inc. (TPST)
NASDAQ: TPST · Real-Time Price · USD
10.27
-0.51 (-4.73%)
At close: Oct 10, 2025, 4:00 PM EDT
10.10
-0.17 (-1.66%)
After-hours: Oct 10, 2025, 7:49 PM EDT
Tempest Therapeutics Employees
Tempest Therapeutics had 24 employees as of December 31, 2024. The number of employees increased by 7 or 41.18% compared to the previous year.
Employees
24
Change (1Y)
7
Growth (1Y)
41.18%
Revenue / Employee
n/a
Profits / Employee
-$1,795,792
Market Cap
45.60M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 24 | 7 | 41.18% |
| Dec 31, 2023 | 17 | -2 | -10.53% |
| Dec 31, 2022 | 19 | 2 | 11.76% |
| Dec 31, 2021 | 17 | 3 | 21.43% |
| Dec 31, 2020 | 14 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
TPST News
- 2 months ago - Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 3 months ago - Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China - GlobeNewsWire
- 4 months ago - Tempest Announces $4.6 Million Registered Direct Offering of Common Stock - GlobeNewsWire
- 4 months ago - Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC - GlobeNewsWire
- 5 months ago - Tempest Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 5 months ago - Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting - GlobeNewsWire
- 6 months ago - Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP - GlobeNewsWire
- 6 months ago - Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value - GlobeNewsWire